Lenvatol 10mg

Lenvatol is a medication used to treat various types of cancer, including thyroid cancer, kidney cancer, and liver cancer. It is an oral medication that works by inhibiting the growth of cancer cells by blocking the activity of several proteins that promote tumor growth and survival.

Composition:

Lenvatol contains Lenvatinib, a medication that is a multikinase inhibitor.

Indications:

Lenvatol is indicated for the treatment of:

1. Thyroid cancer (medullary thyroid cancer)
2. Kidney cancer (advanced renal cell carcinoma)
3. Liver cancer (hepatocellular carcinoma)

Mechanism of Action:

Lenvatinib works by:

1. Inhibiting the activity of several proteins that promote tumor growth and survival, including:
   • VEGFR (vascular endothelial growth factor receptor)
   • FGFR (fibroblast growth factor receptor)
   • PDGFR (platelet-derived growth factor receptor)
   • KIT (proto-oncogene protein c-kit)
2. Blocking the formation of new blood vessels that supply tumors
3. Reducing the growth and proliferation of cancer cells

Dosage and Administration:

The recommended dosage of Lenvatol is:

• 10mg taken orally once daily
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Lenvatol include:

1. Fatigue
2. Hypertension
3. Diarrhea
4. Abdominal pain
5. Nausea and vomiting
6. Anemia
7. Leukopenia
8. Thrombocytopenia

Serious side effects can include:

1. Hypothyroidism
2. Hepatotoxicity
3. Cardiac toxicity (including arrhythmias and hypertension)
4. Gastrointestinal perforation
5. Respiratory problems

Contraindications:

Lenvatol is contraindicated in patients with:

1. Hypersensitivity to Lenvatinib or other multikinase inhibitors
2. Severe liver disease
3. Pregnancy or breastfeeding

Precautions:

1. Patients with a history of hypertension should be closely monitored while receiving Lenvatol.
2. Patients with a history of liver disease should be closely monitored while receiving Lenvatol.
3. Patients with a history of cardiac disease should be closely monitored while receiving Lenvatol.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of nausea or vomiting.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.